AIM Advances Pancreatic Cancer Study, Targets Q1 2027 Data

AIM announced it has advanced its Phase 2 DURIPANC study for pancreatic cancer. The biopharmaceutical company anticipates releasing topline data from the trial in the first quarter of 2027. This progression marks a significant step in the development of its therapeutic candidate for a challenging disease. The DURIPANC study focuses on evaluating the efficacy and safety of AIM's investigational treatment in patients with pancreatic cancer. Successful advancement through clinical stages is crucial for the company's pipeline and future market potential. Investors will closely monitor the trial's progress and the upcoming data release.